ional exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling occupational exposure to hazardous drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006;63:1172-1193.
Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society.
Manufactured by:
Nippon Kayaku Co., Ltd.
Tokyo, Japan
Distributed by:
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA
Rev April 2010
-----------------------------------------
REPRESENTATIVE PACKAGING
See How Supplied section for a complete list of available packages of BLENOXANE.
NDC 0015-3010-20
BLENOXANE®
(bleomycin sulfate for injection, USP)
EQUIVALENT TO
15 units bleomycin
Rx only
|
